Fabrication and Evaluation of PCL/PLGA/β-TCP Spiral-Structured Scaffolds for Bone Tissue Engineering
Bioengineering · 19.07.2024 · 11 (7) · 732
DOI: 10.3390/bioengineering11070732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering, online erschienen am 19.07.2024. Verfasst von Weiwei Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Charles V. Schaefer School of Engineering and Sciences, Stevens Institute of Technology, Hoboken, NJ 07030, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the US Army Medical Research Acquisition Activity (USAMRAA) through the CDMRP Peer-Reviewed Medical Research Program, the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health, U.S. Army Medical Research Acquisition Activity (USAMRAA).
Abstract (Originalsprache)
Natural bone is a complex material that has been carefully designed. To prepare a successful bone substitute, two challenging conditions need to be met: biocompatible and bioactive materials for cell proliferation and differentiation, and appropriate mechanical stability after implantation. Therefore, a hybrid Poly ε-caprolactone/Poly(lactic-co-glycolide)/β-tricalcium phosphate (PCL/PLGA/β-TCP) scaffold has been introduced as a suitable composition that satisfies the above two conditions. The blended PCL and PLGA can improve the scaffold’s mechanical properties and biocompatibility compared to single PCL or PLGA scaffolds. In addition, the incorporated β-TCP increases the mechanical strength and osteogenic potential of PCL/PLGA scaffolds, while the polymer improves the mechanical stability of ceramic scaffolds. The PCL/PLGA/β-TCP scaffold is designed using spiral structures to provide a much better transport system through the gaps between spiral walls than conventional cylindrical scaffolds. Human fetal osteoblasts (hFOBs) were cultured on spiral PCL/PLGA/β-TCP (PPBS), cylindrical PCL/PLGA/β-TCP (PPBC), and cylindrical PCL scaffolds for a total of 28 days. The cell proliferation, viability, and osteogenic differentiation capabilities were analyzed. Compared with PCL and PPBC scaffolds, the PPBS scaffold exhibits great biocompatibility and potential to stimulate cell proliferation and differentiation and, therefore, can serve as a bone substitute for bone tissue regeneration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Charles V. Schaefer School of Engineering and Sciences, Stevens Institute of Technology, Hoboken, NJ 07030, USA.
- Department of Chemistry and Chemical Biology, Charles V. Schaefer School of Engineering and Sciences, Stevens Institute of Technology, Hoboken, NJ 07030, USA.
ORCID-Profile: Weiwei Wang, Xiaojun Yu
Förderung
- the US Army Medical Research Acquisition Activity (USAMRAA) through the CDMRP Peer-Reviewed Medical Research Program
- the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health
- U.S. Army Medical Research Acquisition Activity (USAMRAA)
- National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health
Zitieren
APA
Wang, W., Zhou, X., Wang, H., Zhou, G., & Yu, X. (2024). Fabrication and Evaluation of PCL/PLGA/β-TCP Spiral-Structured Scaffolds for Bone Tissue Engineering. Bioengineering, 11(7), 732. https://doi.org/10.3390/bioengineering11070732
Vancouver
Wang W, Zhou X, Wang H, Zhou G, Yu X. Fabrication and Evaluation of PCL/PLGA/β-TCP Spiral-Structured Scaffolds for Bone Tissue Engineering. Bioengineering. 2024;11(7):732. doi:10.3390/bioengineering11070732
BibTeX
@article{Wang2024,
author = {Wang, Weiwei and Zhou, Xiaqing and Wang, Haoyu and Zhou, Gan and Yu, Xiaojun},
title = {Fabrication and Evaluation of PCL/PLGA/β-TCP Spiral-Structured Scaffolds for Bone Tissue Engineering},
journal = {Bioengineering},
year = {2024},
volume = {11},
number = {7},
pages = {732},
doi = {10.3390/bioengineering11070732}
}
EUVIMED